Transaction #8965 · Form 4 · 0001628280-25-052717
Humacyte, Inc. · Stock award · Stock Options (right to buy)
Humacyte, Inc. · Transacted November 16, 2025 · Filed November 17, 2025
What does this filing report?
An SEC Form 4 filing for Humacyte, Inc. records a stock award involving Stock Options (right to buy) on November 16, 2025. The reported quantity was 311,100. The filing date is November 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Humacyte, Inc.
- Company CIK
- 0001818382
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 311,100
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 311,100
- Ownership description
- By spouse
- SEC acceptance time
- Nov 17, 2025, 5:49 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Dougan Brady W ↗
Director
CIK 0001878020
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 311,100
- Conversion / exercise price
- 1.23
- Exercise date
- Not reported
- Expiration date
- November 16, 2035
Filing footnotes & remarks
- F1
- The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.